[ Qiagen Suzhou Translational Medicine raises $25.73M in Series A ]

Qiagen Suzhou Translational Medicine has raised $25.73 million in Series A  funding.

Founded in 2013, Qiagen Suzhou Translational Medicine provides services including biomarker R&D and development of companion diagnostics.

The company plans to build a GMP facility for R&D and production, expand its sales channels, and develop and commercialize its own companion diagnostics for immunotherapies and tumor-targeted candidates.

Funding  Series A
Founded  2013
Country  China
City  Suzhou, Jiangsu
Founder / CEO  Nick Zhang
Deal Size  $25.73M
Investors  BoYueZhiYuan Capital
 Angel Medical Instrument
 Quanchuang Capital
 New Horizon Capital
 Qiming Venture Partners
Previous Investors  /